Nurix Therapeutics Q2 EPS $(0.52) Beats $(0.75) Estimate, Sales $44.056M Beat $17.009M Estimate

Benzinga07-10

Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.75) by 30.76 percent. This is a 26.76 percent increase over losses of $(0.71) per share from the same period last year. The company reported quarterly sales of $44.056 million which beat the analyst consensus estimate of $17.009 million by 159.02 percent. This is a 264.34 percent increase over sales of $12.092 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法